Brief: Paratek Announces Top Line Results Of Phase 2 Clinical Studies Of Omadacycline In UTI
31/10/2019 21:32
Oct 31 (Reuters) - Paratek Pharmaceuticals Inc PRTK.O :
* PARATEK ANNOUNCES TOP LINE RESULTS OF PHASE 2 CLINICAL
STUDIES
OF OMADACYCLINE IN URINARY TRACT INFECTIONS
* PARATEK PHARMACEUTICALS - IN BOTH STUDIES, OMADACYCLINE
SHOWED
GENERALLY COMPARABLE LEVELS OF CLINICAL SUCCESS TO EITHER
NITROFURANTOIN/ LEVOFLOXACIN
* PARATEK PHARMACEUTICALS - OMADACYCLINE WAS GENERALLY SAFE
AND
WELL-TOLERATED IN BOTH STUDIES
Source text for Eikon: ID:nGNX32zTzd
Further company coverage: PRTK.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Paratek Pharmaceuticals
See all newsNovo Holdings closes $462 mln acquisition of Paratek Pharmaceuticals
Brief: Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Responds to Demand Letters From 11 Stockholders Alleging 'Misleading', Incomplete Statements In Proxy Statement Filed On June 30
Brief: Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Announces Second Quarter 2023 Revenue Of $40.0 Million